Skip to main content
Premium Trial:

Request an Annual Quote

Luminex Expects Significant Revenue Shortfall in Q1

NEW YORK, April 2 - Luminex said on Monday that it expects first-quarter financial results to be "significantly" lower than its prior guidance.

With its rejiggered outlook, triggered by continued delays in the commercialization timetables of its customers, Luminex now expects a wider-than-expected first-quarter loss of $.20 to $.23 per share on revenue of $2.2 million to $2.7 million.
 
Luminex said its revenue continues to be bruised by the "lengthy and unpredictable" sales cycle for its products, including its xMAP bioassay technology.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.